ReviewClinics in chest medicine2011
Lung cancer: epidemiology, etiology, and prevention.
Review in Clinics in chest medicine, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 637 papers, 7 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Retreatment With 1st Generation EGFR TKIs in Sensitizing EGFR Mutation Positive Non-Squamous Cell Carcinoma Patients Who Previously Treated With EGFR TKI and Cytotoxic Chemotherapy
Monitoring and Telecoaching of Physical Activity in Patients With Stage III and IV Non-small Cell Lung Cancer
Who cites it
637 citing papers in PubMed, 7 syntheses or guidelines pooled it.
- The association between sleep quantity, insomnia and lung cancer risk - A systematic review and meta-analysis.Sleep & breathing = Schlaf & Atmung · 2024Pooled it
- Impact of preoperative chemotherapy on cutaneous wound healing in lung cancer patients: A meta-analysis.International wound journal · 2024Pooled it
- Is there a role for fibreoptic bronchoscopy in patients presenting with haemoptysis and negative CT? A systematic review and meta-analysis.BMJ open respiratory research · 2024Pooled it
- Correlation between rs1800871, rs1800872 and rs1800896 Polymorphisms at IL-10 Gene and Lung Cancer Risk.Asian Pacific journal of cancer prevention : APJCP · 2024Pooled it
- Efficacy and safety of veliparib plus chemotherapy for the treatment of lung cancer: A systematic review of clinical trials.PloS one · 2023Pooled it
- Preoperative exercise training for people with non-small cell lung cancer.The Cochrane database of systematic reviews · 2022Pooled it
- Inhaled corticosteroids, COPD, and the incidence of lung cancer: a systematic review and dose response meta-analysis.BMC pulmonary medicine · 2022Pooled it
- A Hypergraph-Based Model for Predicting Potential Drug Combinations in Cancer Therapy.Interdisciplinary sciences, computational life sciences · 2026Article
- Prognostic ımpact of vascular, lymphatic, and perineural ınvasion in surgically resected, non-adjuvantly treated stage IA non-small-cell lung cancer: a retrospective cohort study.Updates in surgery · 2026Article
- Association between the presence of EGFR or ALK mutations and the location of primary non-small cell lung cancer, as well as metabolic activity observed onOncology letters · 2026Article
- Characterization of Patients with Non-Small Cell Lung Cancer Using Machine Learning Tools: Relationship with Prognostic Biomarkers and Overall Survival-A Pilot Study.Journal of clinical medicine · 2026Article
- Occupational benzene exposure and risk of lung cancer: a systematic review and meta-analysis.European journal of epidemiology · 2026Review
- Rho-associated kinase (ROCK)-associated proteins and genes-encoded proteins upregulated in lung squamous cell carcinoma (LUSC).Journal of the Egyptian National Cancer Institute · 2026Article
- Decoding Prognostic Signatures in Brain Metastatic Non-Small-Cell Lung Cancer via Integrated Multi-Omics and Network Analysis.International journal of molecular sciences · 2026Article
- Real-world effectiveness and safety of adjuvant atezolizumab in pathological stage IIA-IIIB non-small cell lung cancer following curative surgery.Journal of thoracic disease · 2026Article
- Bridging Inflammation and Oncology: The Role and Therapeutic Potential of Macrophage Migration Inhibitory Factor in Lung Cancer.International journal of molecular sciences · 2026Review
- Identification and evaluation of tumor pyroptosis-associated antigens for design a vaccine candidate against lung cancer.Scientific reports · 2026Article
- Therapeutic potential of plant-derived tannic acid on pulmonary disorders in experimental models.Inflammopharmacology · 2026Review
- Thiol/Disulfide Homeostasis in Lung Cancer: Insights from a Clinical Study.Antioxidants (Basel, Switzerland) · 2026Article
- Advanced Multiscale Inhalation Platforms for Treatment of Pulmonary Diseases.International journal of nanomedicine · 2026Review
577 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Lung cancer is the leading cause of cancer death in the United States and around the world. A vast majority of lung cancer deaths are attributable to cigarette smoking, and curbing the rates of cigarette smoking is imperative. Understanding the epidemiology and causal factors of lung cancer can provide additional foundation for disease prevention. This article focuses on modifiable risk factors, including tobacco smoking, occupational carcinogens, diet, and ionizing radiation. It also discusses briefly the molecular and genetic aspects of lung carcinogenesis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.